Bisulli F, Baruzzi A, Rosati A, Riva R, Avoni P, Cerullo A, Tinuper P
Neurological Institute. University of Bologna, Via Ugo Foscolo 7, 40123 Bologna, Italy.
Epileptic Disord. 2001 Sep;3(3):151-6.
To evaluate the efficacy of lamotrigine (LTG) add-on therapy in drug-resistant, partial epilepsy with epileptic drop attacks (EDA) and secondary bilateral synchrony (SBS) on EEG.
We carried out a single-center, open-label, prospective study on a restricted group of patients experiencing an EDA frequency of at least one/month during the previous year regardless of multiple antiepileptic drug (AED) trials. Study design consisted of three phases: a 3-month baseline period, a 4-month period in which LTG was titrated and a 9-month maintenance dose observational period. LTG add-on therapy depended on valproate (VPA) association, with a maximum of 200 mg/day with VPA and 600 mg/day in the absence of VPA. Every three months, patients underwent clinical, hematological and EEG evaluation including plasma level of AEDs. To assess the efficacy of LTG add-on therapy, patients were required to keep a detailed seizure diary throughout the study.
Fourteen patients (nine men and five women), aged from 21 to 51, were included in the study. All of them had complex partial seizures (CPS), besides EDA, and half of them had secondarily generalized seizures (SGS). Two of the 14 patients had to stop LTG due to side effects, although one of them was seizure-free after LTG. Twelve patients completed the study. The improvement was more than 50% for every type of seizure. SGS disappeared in three cases and improved by more than 50% in another three cases. EDA disappeared in six patients; and improved with more than 50% EDA reduction in five patients. CPS disappeared in two patients and improved by more than 50% in eight. EEG improved in nine cases, with SBS disappearing in six patients.
We have demonstrated a good efficacy of LTG adjunctive therapy on EDA. Results include control of SGS and improvement of EEG tracing.
评估拉莫三嗪(LTG)添加疗法对耐药性部分性癫痫伴癫痫性跌倒发作(EDA)和脑电图显示继发性双侧同步(SBS)的疗效。
我们对一组特定患者进行了一项单中心、开放标签的前瞻性研究,这些患者在过去一年中EDA发作频率至少为每月一次,无论之前进行过多少次抗癫痫药物(AED)试验。研究设计包括三个阶段:3个月的基线期、4个月的LTG滴定期和9个月的维持剂量观察期。LTG添加疗法取决于丙戊酸盐(VPA)的联合使用情况,与VPA联合使用时最大剂量为200毫克/天,无VPA时为600毫克/天。每三个月,患者接受临床、血液学和脑电图评估,包括AEDs的血浆水平。为评估LTG添加疗法的疗效,要求患者在整个研究过程中记录详细的癫痫发作日记。
14名患者(9名男性和5名女性),年龄在21至51岁之间,被纳入研究。他们均有复杂部分性发作(CPS),除EDA外,其中一半患者有继发性全身性发作(SGS)。14名患者中有2名因副作用不得不停用LTG,尽管其中1名患者在使用LTG后无癫痫发作。12名患者完成了研究。每种癫痫发作类型的改善均超过50%。3例SGS消失,另外3例改善超过50%。6例患者的EDA消失;5例患者的EDA减少超过50%而得到改善。2例患者的CPS消失,8例患者的CPS改善超过50%。9例患者的脑电图得到改善,6例患者的SBS消失。
我们已证明LTG辅助疗法对EDA有良好疗效。结果包括对SGS的控制和脑电图描记的改善。